Dr. John J. Albers

• Vuletic S, Jin LW, Marcovina SM, Peskind ER, Möller T, Albers JJ (2003) Widespread distribution of phospholipid transfer protein (PLTP) in human central nervous system: evidence for PLTP synthesis by glia and neurons and for increased levels in Alzheimer's disease. J Lipid Res 44, 1113-1123.
• Vuletic S, Peskind ER, Marcovina SM, Quinn JF, Cheung MC, Kennedy H, Kaye JA, Jin L-W, Albers JJ (2005) Reduced CSF PLTP activity in Alzheimer's Disease and other neurological diseases: PLTP induces apoE secretion in primary human astrocytes in vitro. J Neurosci Res 80, 406-413.
• Vuletic S, Riekse RG, Marcovina SM, Peskind ER, Hazzard WB, Albers JJ (2006) Statins of different brain penetrability differentially affect CSF PLTP activity. Dement Geriatric Cogn Disord 22, 392-398.
• Vuletic S, Li G, Peskind ER, Kennedy H, Marcovina SM, Levernz JB, Petrie E, Lee VMY, Galasko D, Schellenberg GD, Albers JJ (2008)  Apolipoprotein E highly correlates with AβPP- and tau-related markers in human cerebrospinal fluid. J Alzheimers Dis 15, 409-417.

Dr. Sarah Aldred

• Aldred S, Sozzi T, Mudway I, Grant MM, Neubert H, Kelly FJ, Griffiths HR (2006) Alpha tocopherol supplementation elevates plasma apolipoprotein A1 isoforms in normal healthy subjects. Proteomics 6, 1695-1703.
• Aldred S (2007) Oxidative and nitrative changes seen in lipoproteins
  following exercise. Atherosclerosis 192, 1-8.
• Aldred S, Rohalu MS, Edwards KM, Burns VE (2009) Altered DHEA and DHEAS response to exercise in healthy older adults. J Ageing Physical Activity, in press.
• Bennett S, Grant MM, Aldred S (2009) Oxidative stress in vascular dementia and Alzheimer's disease: a common pathology. J Alzheimers Dis, in press.

Marialaura Amadio

• Amadio M, Pascale A, Wang J, Ho L, Quattrone A, Gandy S, Haroutunian V, Racchi M, Pasinetti GM (2009) nELAV proteins alteration in Alzheimer's disease brain: a novel putative target for Aβ reverberating on APP processing. J Alzheimers Dis, in press.

Peter Andrews, Ph.D.

• Bachis A, Aden SA, Nosheny RL, Andrews PM, Mocchetti I (2006) Axonal transport of HIV-1 envelope protein gp120 causes neuronal apoptosis. J Neurosci 26, 6771-6780.
• Andrews P, Zhao X, Allen J, Li F, Chang M (2007) A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs (NSAIDs) and their derivatives against cancer cells in vitro. Cancer Chemo Pharm 61, 203-214.
• Andrews PM, Chen Y, Onozato M, Huang S-W, Adler DC, Huber R, Jiang J, Barry S, Cable A, Fujimoto JG (2008) High-resolution optical coherence tomography imaging of the living kidney. Lab Invest 88, 441-449.
• Zhao X, Rebeck GW, Hoe H-S, Andrews PM (2008) Tarenflurbil protection from cytotoxicity is associated with an up-regulation of neurotrophins. J Alzheimers Dis 15, 397-407.

Sandrine Andrieu, MD, PhD

• Coley N, Andrieu S, Gardette V, Gillette-Guyonnet S, Sanz C, Vellas B, Grand A (2008) Dementia prevention: methodological explanations for inconsistent results. Epidemiol Rev 30, 35-66.
• Andrieu S, Ousset PJ, Coley N, Ouzid M, Mathiex-Fortunet H, Vellas B (2008) GuidAge study GROUP. GuidAge study: a 5-year double blind, randomised trial of EGb 761 for the prevention of Alzheimer's disease in elderly subjects with memory complaints. i. rationale, design and baseline data. Curr Alzheimer Res 5, 406-415.
• Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G; European Task Force Group (2008) Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 7, 436-450.
• Vellas B, Coley N, Andrieu S (2008) Disease modifying trials in Alzheimer's disease: perspectives for the future. J Alzheimers Dis 15, 289-301.

Francesco Angelucci

• Angelucci F, Ricci V, Pomponi M, Conte G, Mathé AA, Attilio Tonali P, Bria P (2007) Chronic heroin and cocaine abuse is associated with decreased serum concentrations of the nerve growth factor and brain-derived neurotrophic factor. J Psychopharmacol 21, 820-825.
• Di Lazzaro V, Profice P, Pilato F, Dileone M, Florio L, Tonali PA, Angelucci F (2007) BDNF plasma levels in acute stroke. Neurosci Lett 422, 128-130.
• Angelucci F, Ricci V, Spalletta G, Pomponi M, Tonioni F, Caltagirone C, Bria P (2008) Reduced serum concentrations of nerve growth factor, but not brain-derived neurotrophic factor, in chronic cannabis abusers. Eur Neuropsychopharmacol 18, 882-887.
• Angelucci F, Bernardini S, Gravina P, Bellincampi L, Trequattrini A, Di Iulio F, Vanni D, Federici G, Caltagirone C, Bossù P, Spalletta G (2009) Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A (102T/C) receptor polymorphism in Alzheimer’s disease: a 3-year follow-up longitudinal study. J Alzheimers Dis, in press.

Craig S. Atwood, Ph.D.

• Bowen RL, Verdile G, Liu T, Perry G, Smith MA, Martins RN, Atwood CS (2004) Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-ß protein precursor and amyloid-ß deposition. J Biol Chem 279, 20539-20545.
• Liu T, Perry G, Chan HW, Verdile G, Martins RN, Smith MA, Atwood CS (2004) Amyloid-ß-induced toxicity of primary neurons is dependent upon differentiation associated increases in tau and cyclin-dependent kinase 5. J Neurochem 88, 554-563.
• Wilson, A.C., Salamat, S., Haasl, R.J., Roche, K.M., Karande, A., Vadakkadath Meethal, S., Terasawa, E., Bowen, R.L. and Atwood, C.S. (2006). Human extra-pituitary neurons possess GnRH I receptors that respond to GnRH by expressing luteinizing hormone. J Endocrinol 191, 651-665.
• Porayette, P., Gallego, M.J., Kaltcheva, M.M., Vadakkadath Meethal, S. and Atwood, C.S. (2007). Amyloid-ß precursor protein expression and modulation in human embryonic stem cells: A novel role for human chorionic gonadotropin. Biochem Biophys Res Commun 364, 522-527.

top

Jesús Ávila

• Perez M, Santa-María I, Tortosa E, Cuadros R, Del Valle M, Hernández F, Moreno FJ, Avila J (2007) The role of the VQIVYK peptide in tau protein phosphorylation. J Neurochem 103, 1447-1460.
• Goñi-Oliver P, Lucas JJ, Avila J, Hernández F (2007)  N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem 282, 22406-22413.
• Gómez-Sintes R, Hernández F, Bortolozzi A, Artigas F, Avila J, Zaratin P, Gotteland JP, Lucas JJ (2007) Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO J 26, 2743-2754.
• Hooper C, Markevich V, Plattner F, Killick R, Schofield E, Engel T, Hernandez F, Anderton B, Rosenblum K, Bliss T, Cooke SF, Avila J, Lucas JJ, Giese KP, Stephenson J, Lovestone S (2007) Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci 25, 81-86.

William A. Banks, MD

• Poon HF, Farr SA, Banks WA, Pierce WM, Klein JB, Morley JE, Butterfield AD (2005) Proteomic identification of less oxidized brain proteins in aged senescence-accelerated mice following administration of antisense oligonucleotide directed at the Aβ region of amyloid precursor protein. Mol Brain Res 138, 8-16.
• Mare M, Penugonda S, Robinson SM, Dohgu S, Banks WA, Ercal N (2007) Copper complexing decreases the ability of amyloid beta peptide to cross the BBB and enter brain parenchyma. Peptides 28, 1424-1432.
• Petursdottir AL, Farr SA, Morley JE, Banks WA, Skuladottir GV (2007) Lipid peroxidation in brain during aging in the senescence-accelerated mouse (SAM). Neurobiol Aging 28, 1170-1178.
• Banks WA, Farr SA, Morley JE, Wolf KM, Geylis V, Steinitz M (2007) Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: An age-related selective uptake with reversal of learning impairment. Exp Neurol 206, 248-256.

Thomas Bayer, Ph.D.

• Bayer TA , Schäfer S, Simons A, Kemmling, Kamer T, Tepest R, Eckert A, Schüssel K, Eikenberg O, Sturchler-Pierrat, Abramowski D, Staufenbiel, Multhaup G (2003) Dietary Cu stabilizes brain SOD-1 activity and reduces amyloid Aß production in APP23 transgenic mice. PNAS 100, 14187-14192.
• Schmitz C, Rutten BPF, Pielen A, Schäfer S, Wirths O, Tremp G, Czech C, Blanchard V, Multhaup G, Korr H, Steinbusch HWM, Pradier L, Bayer TA (2004) Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am J Pathol 164, 1495-1502.
• Wirths O, Czech C, Feldmann F, Blanchard V, Tremp G, Multhaup G, Beyreuther K, Pradier L, Bayer TA (2002) Intraneuronal APP/Abeta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice. Brain Pathol 12, 275-286.
• Wirths O, Multhaup G, Bayer TA (2004) A modified ß-amyloid hypothesis: intraneuronal accumulation of the ß-amyloid peptide  The first step in a fatal cascade. J Neurochem 91, 513-520.

Frederick P. Bellinger, Ph.D.

• Bellinger FP, Wilce PA, Bedi KS, Wilson P (2002) Long lasting synaptic modification in the rat hippocampus resulting from NMDA receptor blockade during development. Synapse 93, 95-101.
• Bark C, Bellinger FP, Kaushal A, Mathews JR, Partridge LD, Wilson MC (2004) Developmentally regulated switch in alternatively spliced SNAP-25 isoforms alters facilitation of synaptic transmission. J Neurosci 24, 8796-8805.
• Bellinger FP, Davidson M, Bedi KL, Wilce P (2005) Maternal separation reduces NMDA receptor levels in the neonatal rat hippocampus. Brain Res 1067, 154-157.
• Bellinger FP, He QP, Bellinger MT, Lin Y, Raman AV, White LR, Berry MJ (2008) Association of selenoprotein P with Alzheimer’s pathology in human cortex. J Alzheimers Dis 15, 465-472.

Angelika Bierhaus, Ph.D.

• Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert P, Chen J, Hong M, Luther T, Henle T, Klöting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith MA, Perry G, Schmidt AM, Stern DM, Häring HU, Schleicher E, Nawroth PP (2001) Diabetes-associated sustained activation of the transcription factor NF-kB. Diabetes 50, 2792-2809.
• Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D, Ferstl R, von Eynatten M, Wendt Th, Rudofsky G, Joswig M, Morcos M, Schwaninger M, McEwen B, Kirschbaum C, Nawroth PP (2003) A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci 100, 1920-1925.
• Bierhaus A, Haslbeck KM, Humpert PM, Liliensiek B, Dehmer T, Morcos M, Sayed AA, Andrassy M, Schiekofer S, Schneider J, Schulz J, Heuss D, Neundörfer B, Dierl S, Huber J, Tritschler H, Schmidt AM, Schwaninger M, Häring HU, Schleicher E, Stern DM, Kasper M, Arnold B, Nawroth PP (2004) Loss of pain perception in diabetic neuropathy is dependent on a receptor of the immune globulin superfamily. J Clin Invest 114, 1741- 1751.
• Bierhaus A, Nawroth PP (2005) Posttranslational modification of lipoproteins - a fatal attraction in metabolic diseases? J Alzheimers Dis 7, 315-317.

Garth Bissette, Ph.D.

• Bissette G, Smith WH, Dole KC, Crain B, Ghanbari H, Miller B, Nemeroff CB (1991) Alterations in Alzheimer's disease-associated protein in Alzheimer's disease frontal and temporal cortex. Arch Gen Psychiatry 48, 1009-1012.
• Slotkin TA, Nemeroff CB, Bissette G, Seidler FJ (1994) Overexpression of the high affinity choline transporter in cortical regions affected by Alzheimer's Disease: Evidence from rapid autopsy studies. J Clin Invest 94, 696-702.
• Bissette G, Cook L, Smith W, Dole KC, Crain B, Nemeroff CB (1998) Regional neuropeptide pathology in Alzheimer’s disease: Corticotropin-releasing factor and Somatostatin. J Alzheimers Dis 1, 91-105.
• Horgan J, Miguel-Hidalgo J, Thrasher M, Bissette G (2007) Longitudinal brain corticotropin-releasing factor and ssomatostatin in a transgenic mouse (Tg2576) model of Alzheimers disease. J Alzheimers Dis 12, 115-127.

Professor Alexander Boldyrev

• Boldyrev A, Johnson P (2002) Histidine containing dipeptides as natiral protectors against oxidative stress. In: Oxidative Stress at Molecular, Cellular and Organ Levels. Johnson P, Boldyrev A, Eds., 101-113.
• Boldyrev A, Bulygina E, Carpenter D, Schoner W (2003) Glutamate receptors communicate with Na/K-ATPase in rat cerebellum granule cells. J Mol Neurosci 21, 213-222.
• Boldyrev A, Kazey V, Leinsooa T, Mashkina A, Tyulina O, Johnson P, Tuneva J, Chittur S, Carpenter D (2004) Rodent lymphocytes express functionally active glutamate receptors. Biochem Biophys Res Commun 324, 133-139.
• Boldyrev A, Beresov T, Koudinov A, Carpenter D (2004) Amyloid β induced cell death is independent of free radicals. J Alzheimers Dis 6, 584-589.

top

Gene Bowman, ND

• Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF (2007) Blood-brain barrier in Alzheimer’s disease: stability and functional significance. Neurology 68, 1809-1814.
• Bowman GL, Baxter J, Frei B, Traber M, Leonard S, Kaye JA, Oken BS, Shannon J, Quinn JF (2008) A plasma panel of nutrient biomarkers is more reliable than food frequency questionnaire in subjects at risk for dementia. American Academy of Neurology, April 2008, Chicago, IL.
• Bowman GL, Quinn JF (2008) Alzheimer’s disease and the blood-brain barrier: past, present and future. Aging Health 4, 47-57.
• Bowman GL, Dodge H, Calabrese C, Oken BS, Frei B, Kaye JA, Quinn JF (2009) Ascorbic acid and rates of cognitive decline in Alzheimer’s disease. J Alzheimers Dis, in press.

Robert Bowser, Ph.D.

• Wilson C, Henry S, Smith MA, Bowser R (2004) The p53 homologue p73 accumulates in the nucleus and localizes to neurites and neurofibrillary tangles in Alzheimer disease brain. Neuropath Appl Neurobiol 30, 19-29.
• Yu X, Caltagarone J, Smith MA, Bowser R (2005) DNA damage induces cdk2 protein levels and histone H2B phosphorylation in SH-SY5Y neuroblastoma cells. J Alzheimers Dis 8, 7-21.
• Previll LA, Crosby ME, Castellani RJ, Bowser R, Perry G, Smith MA, Zhu X (2007) Increased expression of p130 in Alzheimer Disease. Neurochem Res 32, 639-644.
• Caltagarone J, Jing Z, Bowser, R (2007) Focal adhesions regulate Aβ signaling and cell death in Alzheimer’s disease. Biochim Biophys Acta 1772, 438-445.

Amalia Bruni

• Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland RP, Inzelberg R, Hampe W, Bujo H, Song YQ, Andersen OM, Willnow TE, Graff-Radford N, Petersen RC, Dickson D, Der SD, Fraser PE, Schmitt-Ulms G, Younkin S, Mayeux R, Farrer LA, St George-Hyslop P (2007) The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer’s disease. Nat Genet 39, 168-177.
• Bruni AC, Momeni P, Bernardi L, Tomaino C, Frangipane F, Elder J, Kawarai T, Sato C, Pradella S, Wakutani Y, Anfossi M, Gallo M, Geracitano S, Costanzo A, Smirne N, Curcio SAM, Mirabelli M, Puccio G, Colao R, Maletta RG, Kertesz A, St George-Hyslop P, Hardy J, Rogaeva E (2007) Heterogeneity within a large inbred kindred with frontotemporal dementia: a novel progranulin mutation. Neurology 69, 140-147.
• Bernardi L, Tomaino C, Anfossi M, Gallo M, Geracitano S, Puccio G, Colao R, Frangipane F, Mirabelli M, Smirne N, Maletta RG, Bruni AC (2008) Late onset familial Alzheimer’s disease: novel Presenilin 2 mutation and PS1 E318G polymorphism. J Neurol 255, 604-606.
• Bernardi L, Tomaino C, Anfossi M, Gallo M, Geracitano S, Costanzo A, Ferrise F, Colao R, Puccio G, Frangipane F, Curcio Sam, Mirabelli M, Smirne N, Calignano C, Paonessa A, Muraca Mg, Chieffallo C, Iapaolo D, Maletta RG, Bruni AC (2008) Novel PSEN1 and PGRN mutations in Early-onset familial frontotemporal dementia. Neurobiol Aging, in press.

Prof. Ashley Bush

• Puglielli L, Friedlich AL, Setchell KDR, Nagano S, Opazo C, Cherny RA, Barnham KJ, Wade JD, Melov S, Kovacs DM, Bush AI (2005) Alzheimer’s disease β-amyloid activity mimics cholesterol oxidase. J Clin Invest 115, 2556-2563.
• Opazo C, Luza S, Villemagne V, Volitakis I, Rowe C, Barnham KJ, Strozyk D, Masters CL, Cherny RA, Bush AI (2006) Radioiodinated clioquinol as a biomarker for β-amyloid:Zn2+ complexes in Alzheimer’s disease. Aging Cell 5, 69-79.
• Lannfelt L, Blennow K, Zetterberg H, Båtsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW (2008) Targeting Aβ as a modifying therapy of Alzheimer's disease: safety, efficacy and biomarker findings of a Phase IIa Randomised, Double-Blind Placebo-Controlled trial of PBT2. Lancet Neurol 7, 779-786.
• Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters, CL, Barnham KJ, Bush AI (2008) Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial amyloid beta. Neuron 59, 43-55.

D. Allan Butterfield, Ph.D.

• Butterfield DA, Poon HF, St. Clair D, Keller JN, Pierce WM, Klein JB, Markesbery WR (2006) Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: Insights into the development of Alzheimer's disease. Neurobiol Dis 22, 223-232.
• Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Markesbery WR, Zhou XZ, Lu KP, Butterfield DA (2006) Oxidative modification and down-regulation of Pin 1 in Alzheimer's disease hippocampus: A redox proteomics analysis. Neurobiol Aging 27, 918-925.
• Butterfield DA, Reed T, Newman SF, Sultana R (2007) Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 43, 658-677.
• Opii WO, Joshi G, Head E, Milgram NW, Muggenburg BA, Klein JB, Pierce WM, Cotman CW, Butterfield DA (2008) Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and program of behavioral enrichment: relevance to Alzheimer's disease. Neurobiol Aging 29, 51-70.

Cynthia M. Carlsson, MD, MS

• Carlsson CM, Gleason CE, Asthana S (2005) Alzheimer disease: Update on diagnosis and treatment. Consultant 45, 77-88.
• Ward MA, Carlsson CM, Trivedi MA, Sager MA, Johnson SC (2005) The effect of body mass index on global brain volume in middle-aged adults: a cross-sectional study. BMC Neurology 5, 23.
• Johnson SC, Schmitz TW, Trivedi MA, Ries ML, Torgerson BM, Carlsson CM, Asthana S, Hermann BP, Sager MA (2006) The influence of AD family history and ApoE4 on mesial temporal    lobe activation. J Neurosci 26, 6069-6076.
• Johnson SC, Ries ML, Hess TM, Carlsson CM, Gleason CE, Alexander AL, Rowley HA, Asthana S, Sager MA (2007) Alzheimer disease risk in healthy middle-aged adults affects brain function during self appraisal. Arch Gen Psychiatry 64, 1163-1171.

Gemma Casadesus, Ph.D.

• Casadesus G, Webber KM, Atwood CS, Pappolla MA, Perry G, Bowen RL, Smith MA (2006) Luteinizing hormone modulates cognition and amyloid-β deposition in Alzheimer APP transgenic mice. Biochim Biophys Acta 1762, 447-452.
• Webber KM, Perry G, Smith MA, Casadesus G (2007).The contribution of luteinizing hormone to Alzheimer disease pathogenesis. Clin Med Res 5, 177-183.
• Casadesus G, Milliken EL, Webber KM, Bowen RL, Lei Z, Rao CV, Atwood CS, Perry G, Keri RA, Smith MA (2007) Declines in cognitive performance are associated with increased luteinizing hormone levels in mice. Mol Cell Endocrinol 269, 107-111.
• Pallas M, Camins A, Smith MA, Perry G, Lee HG, Casadesus G (2008) From aging to Alzheimer’s disease: unveiling “the switch” with the senescence-accelerated mouse model (SAMP8). J Alzheimers Dis, in press.

Prof. Fiorella Casamenti

• Baglioni S, Casamenti F, Bucciantini M, Lubeshi L, Taddei N, Chiti F, Dobson CM, Stefani M (2006) Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J Neurosci 26, 8160-8167.
• Bellucci A, Luccarini I, Scali C, Prosperi C, Giovannini MG, Pepeu G, Casamenti F (2006) Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice. Neurobiol Dis 23, 260-272.
• Bellucci A, Rosi MC, Grossi C, Fiorentini A, Luccarini I, Casamenti F (2007) Abnormal processing of tau in the brain of aged TgCRND8 mice. Neurobiol Dis 27, 328-338.
• Pollio G, Hoozemans J, Andersen C, Roncarati R, Rosi MC, van Haastert E, Seredenina T, Diamanti D, Gotta S, Fiorentini A, Magnoni L, Raggiaschi R, Rozemuller A, Casamenti F, Caricasole A, Terstappen GC (2008) Increased expression of the oligopeptidase THOP1 is a neuroprotective response to Abeta toxicity. Neurobiol Dis 31, 145-158.

Rudy J. Castellani, M.D.

• Castellani RJ, Zhu X, Lee HG, Moreira PI, Perry G, Smith MA (2007) Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees? Expert Rev Neurother 7, 473-485.
• Castellani RJ, Honda K, Moreira PI, Liu Q, Siedlak SL, Zhu X, Smith MA, Perry G (2007) Redox active iron at the center of oxidative stress in Alzheimer disease. Neurochem Res 32, 1640-1645.
• Castellani RJ, Marlatt M, Webber KM, Moreira PI, Lee H, Casadesus G, Honda K,  Zhu X, Perry G, Smith MA (2008) Thinking outside the box in Alzheimer disease treatment. In Development of Therapeutic Agents, Gad S (Ed), John Wiley and Sons, in press.
• Castellani RJ, Lee H, Zhu X, Nunomura A, Perry G, Smith MA (2008) Alzheimer’s disease: pathology vs. etiology. Int J Neuroprot Neuroregen, in press.

Ved Chauhan, Ph.D.

• Chauhan, VPS, Chauhan A, Wegiel J (2001) Fibrillar amyloid beta-protein forms a membrane-like hydrophobic domain. NeuroReport 3, 587-590.
• Chauhan V, Sheikh AM, Chauhan A, Spivack WD, Fenko MD, Malik MN (2005) Fibrillar amyloid beta-protein inhibits the activity of high molecular weight protease, and trypsin. J Alzheimers Dis 7, 37-44.
• Chander H, Chauhan A, Wegiel J, Malik M, Sheikh A, Chauhan V (2006) Binding of trypsin to fibrillar amyloid beta-protein. Brain Res 1082, 173-181.
• Chauhan V, Chauhan A (2006) Oxidative stress in Alzheimer's disease. Pathophysiology 13, 195-208.

Shu G. Chen, Ph.D.

• Xie Z, O'Rourke KI, Dong Z, Jenny AL, Langenberg JA, Belay ED, Schonberger LB, Petersen RB, Zou W, Kong Q, Gambetti P, Chen SG (2006) Chronic wasting disease of elk and deer and Creutzfeldt-Jakob disease: Comparative analysis of the scrapie prion protein. J Biol Chem 281, 4199-4206.
• Zhu X, Babar A, Siedlak LS, Yang Q, Ito G, Iwatsubo T, Smith MA, Perry G, Chen SG (2006) LRRK2 in Parkinson's disease and dementia with Lewy bodies. Mol Neurodegener 1, 17.
• Guo L, Gandhi PN, Wang W, Petersen RB, Wilson-Delfosse AL, Chen SG (2007) The Parkinson's disease associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res 313, 3658-3670.
• Gandhi PN, Wang X, Zhu X, Chen SG, Wilson-Delfosse AL (2008) The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J Neurosci Res 86, 1711-1720.

Muhammad Omar Chohan, M.D.

• Chohan MO, Haque N, Alonso A, El-Akkad E, Grundke-Iqbal I, Grover A, Iqbal K (2005) Hyperphosphorylation-induced self assembly of murine tau: a comparison with human tau. J Neural Transm 112, 1035-1047.
• Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H, Grundke-Iqbal I (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739, 198-210.
• Chohan MO, Iqbal K (2005) Estrogens for the Brain. Alzheimer Research Forum, July 28, 2005, http://www.alzforum.org/pap/annotation.asp?powID=45893.
• Chohan MO, Khatoon S, Grundke-Iqbal I, Iqbal K (2006) Involvement of I2pp2a in the abnormal hyperphosphorylation of tau and its reversal by memantine. FEBS Lett 580, 3973-3979.

Leung-Wing Chu, MD, FRCP

• Chu LW, ESK Ma, KKY Lam, MF Chan, DHS Lee (2005) Increased alpha 7 nicotinic acetylcholine receptor protein levels in Alzheimer’s disease patients. Dement Geriatr Cogn Disorder 19, 106-112.
• Chu LW, Yik PY, Mok W, Chung CP (2007) A two-year open-label study of galantamine therapy in Chinese Alzheimer’s disease patients in Hong Kong. Int J Clin Pract 61, 403-410.
• Chu LW, Tam S, Lee PW, Wong RL, Yik PY, Tsui W, Song Y, Cheung BM, Morley JE, Lam KS (2008) Bioavailable testosterone is associated with a reduced risk of amnestic mild cognitive impairment in older men. Clin Endocrinol (Oxf) 68, 589-598.
• Chu LW, Tam S, Lee PWH, Yik PY, Song YQ, Cheung BMY, Lam KSL (2009) Late-life body mass index and waist circumference in amnestic mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis, in press.

Richard Coico, Ph.D.

• Lakshmi Tamma SM, Wu Y, Toporovsky I, Lima V, Coico RF (2001) IgD receptor-mediated signal transduction in T cells. Cell Immunol 207, 110-117.
• Boesen A, Sundar K, Coico R (2005) Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2.1 transgenic mice. Clin Diagn Lab Immunol 12, 1223-1230.
• Sundar K, Boesen A, Coico R (2007) Computational prediction and identification of HLA-A2.1-specific Ebola virus CTL epitopes. Virology 360, 257-263.
• Coico R, Woodruff-Pak D (2008) Immunotherapy for Alzheimer’s disease: harnessing our knowledge of T cell biology using a cholesterol-fed rabbit model. J Alzheimers Dis, in press.

Carol A. Colton, Ph.D.

• Streit WJ, Kincaid-Colton CA (1995) The brain’s immune system. Sci Am 273, 54-61.
• Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP (2006) Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation 3, 27.
• Colton CA, Vitek MP, Wink DA, Xu Q, Cantillana V, Previti ML, Van Nostrand WE, Weinberg JB, Dawson H (2006) NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. roc Natl Acad Sci U S A 103, 12867-12872.
• Vitek MP, Brown CM, Colton CA (2007) APOE genotype-specific differences in the innate immune response. Neurobiol Aging, in press.

Donald J. Connor, Ph.D., Ph.D.

• Griffin-Pierce T, Silverberg N, Connor DJ, Jim M, Peters J, Kaszniak A, Sabbagh MN (2008) Challenges to the recognition and assessment of Alzheimer's disease in American Indians of the southwestern United States. Alzheimers Dement 4, 291-299.
• Connor DJ, Sabbagh MN, Cummings JL (2008) Comment on administration and scoring of the Neuropsychiatric Inventory (NPI) in clinical trials. Alzheimers Dementia, in press.
• Seward JD, Connor DJ (2008) Ethical issues in assigning (or withholding) a diagnosis of malingering. In Neuropsychology of malingering casebook, Morgan JE, Sweet JJ, Eds. Psychology Press, New York, in press.
• Connor DJ, Sabbagh MN (2008) Administration and scoring variance on the ADAS-Cog. J Alzheimers Dis 15, in press.

Dr. James R. Connor

• Zecca L, Youdim MBH, Riederer P, Connor JR, Crichton RR (2004) Iron, brain aging and neurodegenerative disorders. Nature Rev Neurosci 5, 863-873.
• Lee S, Connor JR (2006)Regulation of Hfe by stress factors in BV-2 cells. Neurobiol Aging 26, 803-812.
• Connor JR, Lee SY (2006) HFE mutations and Alzheimer’s Disease. J Alzheimers Dis 10, 267-276.
• House MJ, St. Pierre TG, Kowdley K, Montine T, Connor JR, Beard J, Siddaiah N, Berger J, Shankland E, Jin LW (2007) Correlation of proton transverse relaxation rates (r2) with Iron concentrations in post-mortem brain tissue from Alzheimer’s disease patients. Magnet Reson Med 57, 172-180.

David G. Cook, PhD

• Yang Y, Kinney GA, Spain WJ, Breitner JCS, Cook DG (2004) Presenilin-1 and intracellular calcium stores regulate neuronal glutamate uptake. J Neurochem 88, 1361-1372.
• Ting JT, Kelley BG, Lambert TJ, Cook DG, Sullivan JM (2007) APP overexpression depresses excitatory transmission through both presynaptic and postsynaptic mechanisms. Proc Natl Acad Sci USA 104, 353-358.
• Duerson K, Woltjer RL, Mookherjee P, Leverenz JB, Montine TJ, Bird TD, Pow DV, Rauen T, Cook DG (2008) Detergent-insoluble EAAC1/EAAT3 aberrantly accumulates in hippocampal neurons of Alzheimer's disease patients. Brain Pathol, in press.
• Marcos M, Kulstad JJ, Savard CE, Green PS, Craft S, Watson GS, Cook DG (2008) Peripheral Aβ levels regulate Aβ clearance from the central nervous system. J Alzheimers Dis, in press.

Dr. Eliecer Coto Garcia

• Alvarez V, Mata IF, González P, Lahoz CH, Martínez C, Peña J, Guisasola LM, Coto E (2002) Association between the TNFα-308 A/G polymorphism and the onset-age of Alzheimer disease. Am J Med Genet 114, 574-577.
• Huerta C, Alvarez V, Mata IF, Coto E, Ribacoba R, Martínez C, Blázquez M, Guisasola LM, Salvador C, Lahoz CH, Peña J (2004) Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease. Neurosci Lett 370, 151-154.
• Huerta C, Castro MG, Coto E, Blázquez M, Ribacoba R, Guisasola LM, Salvador C, Martínez C, Lahoz CH, Alvarez V (2005) Mitochondrial DNA polymorphisms and risk of Parkinson's disease in Spanish population. J Neurol Sci 236, 49-54.
• González P, Alvarez V, Menéndez M, Lahoz CH, Martínez C, Corao AI, Calatayud MT, Peña J, García-Castro M, Coto E (2007) Myocyte enhancing factor-2A in Alzheimer's disease: genetic analysis and association with MEF2A-polymorphisms. Neurosci Lett 411, 47-51.

Dr. Dr. Luciano D’Adamio

• Matsuda S, Giliberto L, Matsuda Y, Davies P, McGowan E, Pickford F, Ghiso J, Frangione B, D'Adamio L (2005) The familial dementia BRI2 gene binds the Alzheimer's gene APP and inhibits Aβ production. J Biol Chem 280, 28912-28916.
• Giliberto L, Zhou D, Weldon R, Tamagno E, De Luca P, Tabaton M, D'Adamio L (2008) Evidence that the amyloid-β precursor protein-intracellular domain lowers the stress threshold of neurons and has a "regulated" transcriptional role. Mol Neurodegener 3, 12.
• Matsuda S, Giliberto L, Matsuda Y, McGowan EM, D'Adamio L (2008) BRI2 inhibits amyloid beta-peptide precursor protein processing by interfering with the docking of secretases to the substrate. J Neurosci 28, 8668-8676.
• Zhou D, Zambrano N, Russo T, D’Adamio L (2009) Phosphorylation of a tyrosine in the amyloid-β protein precursor intracellular domain inhibits Fe65 binding and signaling. J Alzheimers Dis, in press.

Suzanne de la Monte, M.D.,M.P.H.

• Etiene D, Kraft J, Ganju N, Gomez-Isla T, Gemelli B, Hyman BT, Hedley-Whyte ET, Wands JR, De La Monte SM (1998) Cerebrovascular pathology contributes to the heterogeneity of Alzheimer's disease. J Alzheimers Dis 1, 119-134.
• de la Monte SM, Wands JR (2001) The AD7c-NTP neuronal thread protein biomarker for detecting Alzheimer's disease. J Alzheimers Dis 3, 345-353.
• de la Monte SM, Chiche J, von dem Bussche A, Sanyal S, Lahousse SA, Janssens SP, Bloch KD (2003) Nitric oxide synthase-3 overexpression causes apoptosis and impairs neuronal mitochondrial function: relevance to Alzheimer's-type neurodegeneration. Lab Invest 83, 287-298.
• de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR (2006) Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis 10, 89-109.

Jack C. de la Torre, M.D., Ph.D.

• de la Torre JC (Ed) (2006) Special Issue: Impact of Heart Disease and Stroke on Alzheimer’s Disease. Neurol Res 28(6).
• Obrenovich ME, Siedlak SL, Smith MA, Chen S, de la Torre JC, Perry G, Aliev G (2006) Overexpression of GRK2 in Alzheimer disease and in a chronic hyperperfusion rat model is an early marker of brain mitochondrial lesion. Neurotox Res 10, 43-56.
• de la Torre JC (2007) Vascular pathways to Alzheimer’s disease. Dementia Forum 2, 2-6.
• de la Torre JC (2008) Pathophysiology of neuronal energy crisis in  Alzheimer’s disease. Neurodegenerative Dis 5, 126-132.

Alexandre Valério de Mendonça

• Rebola N, Sebastião AM, de Mendonça A, Ribeiro JA, Oliveira CR, Cunha RA (2003) Enhanced adenosine A2A receptor facilitation of synaptic transmission in the hippocampus of aged rats. J Neurophysiol 90, 1295-1303.
• Rebola N, Coelho JE, Costenla AR, Lopes LV, Parada A, Oliveira CR, Soares da Silva P, de Mendonça A, Cunha RA (2003) Decrease of adenosine A1 receptor density and of adenosine neuromodulation in the hippocampus of kindled rats. Eur J Neurosci 18, 820-828.
• Almeida T, Rodrigues RJ, de Mendonça A, Ribeiro JA, Cunha RA (2003) Purinergic P2 receptors trigger adenosine release leading to adenosine A2A receptor activation and facilitation of long-term potentiation in rat hippocampal slices. Neuroscience 122, 111-121.
• de Mendonça A, Guerreiro M, Ribeiro F, Mendes T, Garcia C (2004) Mild cognitive impairment: focus on the diagnosis. J Mol Neurosci 23, 13-17.

Dr. Justo Garcia de Yebenes

• Gomez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillan C, Yebenes JG, del Ser T (2003) Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol 60, 1218-1222.
• Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55, 164-173.
• Ros R, Thobois S, Streichenberger N, Kopp N, Sanchez MP, Perez M, Hoenicka J, Avila J, Honnorat J, de Yebenes JG (2005) A new mutation of the {tau} gene, G303V, in early-onset familial progressive supranuclear palsy. Arch Neurol 62, 1444-1450.
• Menenedez J, Rodriguez rroJA, Solano RM, Casarejos MJ, Rodal I, Guerrero R, Sanchez M, Avila J, Mena MA, de Yebenes JG (2006) Suppression of Parkin enhances nigrostriatal and motor neuron lesion in mice over-expressing human-mutated tau. Human Mol Genet 15, 2045-2058.

Sara M. Debanne, Ph.D.

• Petot GJ, Traore F, Debanne SM, Lerner AJ, Friedland RP (2003) Interactions of Apolipoprotein E Genotype and Dietary Fat Intake of Healthy Older Persons During Mid-Adult Life. Metabolism 52, 279-281.
• Mizrahi EH, Jacobsen DW, Debanne SM, Traore F, Lerner AJ, Friedland RP, Petot GJ (2003) Plasma Total Homocysteine  Levels, Dietary Vitamin B6 and Folate Intake in AD and Healthy Aging. J Nutrition Health Aging 7, 160-165.
• Lindstrom HA, Fritsch T, Petot G, Smyth KA, Chen CH, Debanne SM, Lerner AJ, Friedland RP (2005) The relationships between television viewing in midlife and the development of Alzheimer disease in a case-control study. Brain Cogn 58, 157-165.
• Debanne SM, Bielefeld RA, Cheruvu V, Fritsch T, Rowland DY (2007) Association of Alzheimer Disease and Smoking: Bias in Cohort Studies. J Alzheimers Dis 11, 313-321.

Jon Dobson, Ph.D.

• Hautot D Pankhurst QA, Kahn N, Dobson J (2003) Preliminary evaluation of nanoscale biogenic magnetite and Alzheimer's disease. Proc Royal Soc B Biol Lett 270, S62-S64.

• Collingwood JF, Mikhailova A, Davidson M, Batich C, Streit WJ, Terry J, Dobson J (2005) In-situ characterization and mapping of iron compounds in Alzheimer's tissue. J Alzheimers Dis 7, 267-272.
• Khan A, Dobson J, Exley C (2006) The redox cycling of Fe(II) by Aβ42. Free Radic Biol Med 40, 557-569.
• Collingwood JF, Dobson J (2006) Mapping and characterization of iron compounds in Alzheimer's tissue. J Alzheimers Dis 10, 215-222.

Dr. Valeria Drago

• Drago V, Foster PS, Trifiletti D, FitzGerald DB, Crucian GP, Heilman KM (2006) "What's Inside the Art?" The influence of fronto-temporal dementia in art production. Neurology 67, 1285-1287.
• Drago V, Grucian GP, Pisani F, Heilman KM (2006) Distribution of attention as a Function of spatial location: right left; up-down. J Int Neuropsychol Soc 12, 532-537.
• Drago V, Foster FS, Ferri R, Arico D, Heilman KM (2008) Distractibility and Alzheimer disease. The "neglected" phenomenon. J Alzheimers Dis, in press

Professor Murat Emre

• Lippa CF, Emre M (2006) Characterizing clinical phenotypes: the Lewys in their life or the life of their Lewys? Neurology 67, 1910-1911.
• Sahin HA, Emre M, Ziabreva I, Perry E, Celasun B, Perry R (2006) The distribution pattern of pathology and cholinergic deficits in amygdaloid complex in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol (Berl) 111, 115-125.
• Sahin HA, Gurvit IH, Emre M, Hanagasi HA, Bilgic B, Harmanci H (2006) The attitude of elderly lay people towards the symptoms of dementia. Int Psychogeriatr 18, 251-258.
• Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, Cummings JL (2007) Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 78, 36-42.

Adnan Erol, M.D.

• Erol A (2007) Insulin resistance is an evolutionarily conserved physiological mechanism at the cellular level for protection against increased oxidative stress. Bioessays 29, 811-818.
• Erol A (2007) Interleukin-6 (IL-6) is still the leading biomarker of the metabolic and aging related disorders. Med Hypotheses 69, 708.
• Erol A (2007) The functions of PPARs in aging and longevity. PPAR Res, doi:10.1155/2007/39654.
• Erol A (2008) An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer’s disease. J Alzheimers Dis  13, 241-253.

Dr. Christopher Exley

• Exley C, Korchazhkina O, Job D, Strekopytov S, Polwart A & Crome P (2006) Non-invasive therapy to reduce the body burden of aluminium in Alzheimer’s disease. J Alzheimers Dis 10, 17-24.
• Exley C (2006) Aluminium and iron, but neither copper nor zinc, are key to the precipitation of β-sheets of Aβ42 in senile plaque cores in Alzheimer’s disease. J Alzheimers Dis 10, 173-177.
• Exley C, Esiri M (2006) Severe cerebral congophilic angiopathy coincident with increased brain aluminium in a resident of Camelford, Cornwall, UK. J Neurol Neurosurg Psychiatr 77, 877-879.
• Khan A, Dobson J, Exley C (2006) The redox cycling of iron by Aβ42. Free Radic Biol Med 40, 557-569.

Milan Fiala, M.D.

• Fiala M, Lin J, Kermani-Arab V, Ringman J, Gustavson A, Sayre J, Lossinsky AS, Sofroni E, Graves MC, Chiappelli F, Bernard G (2005) Defective phagocytosis of amyloid-β by macrophages of Alzheimer’s disease patients. J Alzheimers Dis 7, 221-232.
• Zhang L, Fiala M, Sayre J, Espinosa A, Mahanian M, Badmaev V, Graves M, Bernard G (2006) Curcuminoids enhance phagocytosis of amyloid-beta by macrophages of Alzheimer’s disease patients. J Alzheimers Dis 10, 1-7.
• Fiala M, Cribbs DH, Rosenthal M, Bernard G (2007) Phagocytosis of amyloid-β and inflammation: two faces of innate immunity in Alzheimer’s disease. J Alzheimers Dis 11, 1-7.
• Fiala M, Liu P, Espinosa-Jeffrey A, Rosenthal M, Ringman J, Sayre J, Zhang L, Zaghi J, Chiang B, Dejbakhsh S, Hui J, Mahanian M, Bernard G, Cashman J (2007) Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer disease patients are improved by bisdemethoxycurcumin. Proc Natl Acad Sci (USA) 104, 12849-12854.

Michael R. Foy, Ph.D.

• Foy MR, Baudry M, Foy JG, Thompson RF (2008) 17beta-estradiol modifies stress-induced and age-related changes in hippocampal synaptic plasticity. Behav Neurosci 122, 301-309.
• Bi R, Foy MR, Thompson RF, Baudry M (2003) Effects of estrogen, age, and calpain on MAP Kinase and NMDA receptors in female rat brain. Neurobiol Aging 24, 977-983.
• Woodruff-Pak D, Thompson RF, Foy MR (2008) A model system approach to the neurobiology of learning, memory, and aging. In Handbook of Theories of Aging, Bentson V, Silverstein M, Putney N, Gans D (Eds). Springer Publishing Company, New York, in press.
• Foy MR, Baudry M, Brinton RD, Thompson RF (2008) Estrogen and hippocampal plasticity in rodent models. J Alzheimers Dis, in press.

Sally Frautschy, PhD

• Ma Q, Yang F. Ubeda O, Beech W, Frautschy SA, Cole GM (2007) Omega-3 fatty acid docosahexaenoic acid increases Sorla/LR11, a sorting protein with reduced expression in sporadic Alzheimer disease (AD): relevance to AD prevention. J Neurosci 27, 14299-14307.
• Kotilinek L, Westerman M, Qinwen W, Lim GP, Simonyi AG, Lesne S, Agnieszka F, Younkin L, Younkin S, Cleary J, Sun G, Cole GM, Frautschy SA, Anwyl R, Ashe KA (2008) Cyclooxygenase-2 inhibition improves amyloid-beta mediated suppression of memory and synaptic plasticity. Brain 131(Pt 3), 651-664.
• Ma Q-L, Yang F, Calon F, Ubeda OJ, Hansen JE, Weisbart RH, Beech W, Frautschy SA, Cole GM (2008) P21-activated kinase aberrant activation and translocation in Alzheimer's disease pathogenesis. J Biol Chem 283, 14132-14143.
• Begum AN, Jones MR, Lim GP, Morihara T, Kim P. Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Teter B, Cole GM, Frautschy SA (2008) Curcumin structure-function, bioavailability, and efficacy models of neuroinflammation and Alzheimer's. J Pharmacol Exp Therapeutics 326, 196-208.

Robert P. Friedland, MD

• Rogaeva E, Meng Y, Leen JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland R, Inzelberg R, Hampe W, Bujo H, Song Y, Andersen O, Graff-Radford N, Petersen R, Dickson D, Der SD, Fraser PE, Schmitt-Ulms G, Younkin S, Mayeux R, Farrer LA, St George-Hyslop P (2007) The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer’s disease. Nat Genet 39, 168-177.
• Taguchi H, Planque S, Nishiyama Y, Symersky J, Boivin S, Szabo P, Friedland RP, Ramsland PA, Edmundson AB, Weksler ME, Paul S (2008) Autoantibody catalyzed hydrolysis of amyloid beta peptide. J Biol Chem 283, 4714-4722.
• Friedland RP, Tedesco JM, Wilson AC, Atwood CS, Smith MA, Perry G, Zagorski G (2008) Antibodies to the potato virus Y bind the Aβ peptide: Immunochemical and NMR studies. J Biol Chem 283, 22550-22556.
• Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, Luchsinger JA, Ogunniyi A, Perry EK, Potocnik F, Prince M, Stewart R, Wimo A, Zhang ZX, Antuono P; World Federation of Neurology Dementia Research Group (2008) Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 7, 812-826.

Daniela Galimberti, PhD

• Dreses-Werringloer U, Lambert JC, Vingtdeux V, Zhao H, Vais H, Siebert A, Jain A, Koppel J, Rovelet-Lecrux A, Hannequin D, Pasquier F, Galimberti D, Scarpini E, Mann D, Lendon C, Campion D, Amouyel P, Davies P, Foskett JK, Campagne F, Marambaud P (2008) A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell 133, 1149-1161.
• Kauwe JS, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, Nowotny P, Galimberti D, Scarpini E, Morris JC, Fagan AM, Holtzman DM, Goate AM (2008) Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A 105, 8050-8054.
• Galimberti D, Scarpini E, Venturelli E, Strobel A, Herterich S, Fenoglio C, Guidi I, Scalabrini D, Cortini F, Bresolin N, Lesch KP, Reif A (2008) Association of a NOS1 promoter repeat with Alzheimer's disease. Neurobiol Aging 29, 1359-1365.
• Galimberti D, Venturelli E, Fenoglio C, Guidi I, Villa C, Bergamaschini L, Cortini F, Scalabrini D, Baron P, Vergani C, Bresolin N, Scarpini E (2008) Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. J Neurol 255, 539-544.

Assoc Prof Brett Garner

• Raftery M, Campbell R, Glaros EN, Rye KA, Halliday GM, Jessup W, Garner B (2005) Phosphorylation of apolipoprotein-E at an atypical protein kinase CK2 PSD/E site in vitro. Biochemistry 44, 7346-7353.
• Kim WS, Suryo Rahmanto A, Kamili A, Rye KA, Guillemin GJ, Gelissen IC, Jessup W, Hill AF, Garner B (2007) Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein-E discs and suppression of amyloid-beta peptide generation. J Biol Chem 282, 2851-2861.
• Chan SL, Kim WS, Kwok JB, Hill AF, Rye KA, Cappai R, Garner B (2008) ATP-binding cassette transporter A7 inhibits amyloid beta production in vitro. J Neurochem 106, 793-804.
• Kim WS, Chan SL, Hill AF, Guillemin GJ, Garner B (2009) Impact of 27-hydroxycholesterol on amyloid-beta peptide production and ATP-binding cassette transporter expression in primary human neurons. J Alzheimers Dis, in press.

Hossein Ghanbari

• Jiang Z-G, Ghanbari HA (2008) Different gene products with similar role in neuronal defense against oxidative stress―heme oxygenase system. In: Genomics and Proteomics, Chapter 6, pps 95-105.
• Jiang Z-G, Ghanbari HA (2009) Pathogenesis and therapeutical strategy of Alzheimer. In: The Role of Oxidative Stresses, Mitochondria Failure and Vascular Hypoperfusion in the Pathogenesis of Alzheimer's Disease, in press.
• Pan W, Dancik CM, Nelson VM, Jiang Z-G, Lebowitz MS, Ghanbari HA (2009) A novel neuroprotectant PAN-811 protects neurons from oxidative stress. Cent Eur J Biol, in press.
• Nelson VM, Pan W, Dancik CM, Jiang Z-G, Lebowitz MS, Ghanbari HA (2009) PAN-811 inhibits oxidative stress induced cell death of human Alzheimer's disease-derived and age-matched olfactory neuroepithelial cells via suppression of intracellular ROS. J Alzheimers Dis, in press.

Dr. Othman Ghribi

• Ghribi O, Golovko MY, Larsen B, Schrag M, Murphy EJ (2006) Deposition of iron and beta-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. J Neurochem 99, 438-449.
• Schrag M, Sharma S, Brown-Borg H, Ghribi O (2008) Hippocampus of Ames dwarf mice is resistant to beta-amyloid-induced tau hyperphosphorylation and changes in apoptosis-regulatory protein levels. Hippocampus 18, 239-244.
• Jaya Prasanthi RP, Schommer E, Thomasson S, Thompson A, Feist G, Ghribi O (2008) Regulation of beta-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer's disease. Mech Ageing Dev, in press.
• Sharma S, Prasanthi R P J, Schommer E, Feist G, Ghribi O (2008) Hypercholesterolemia-induced Abeta accumulation in rabbit brain is associated with alteration in IGF-1 signaling. Neurobiol Dis , in press.

Ewa Golanska, PhD

• Golanska E, Hulas-Bigoszewska K, Rutkiewicz E, Styczynska M, Peplonska B, Barcikowska M, Bratosiewicz-Wasik J, Liberski PP (2004) Polymorphisms within the prion (PrP) and prion-like (Doppel) genes in AD. Neurology 62, 313-315.
• Golanska E, Hulas-Bigoszewska K, Wojcik I, Rieske P, Styczynska M, Peplonska B, Pfeffer A, Luczywek E, Wasiak B, Gabryelewicz T, Religa D, Chodakowska-Zebrowska M, Barcikowska M, Sobow T, Liberski PP (2005) CYP46: a risk factor for Alzheimer's disease or a coincidence? Neurosci Lett 383, 105-108.
• Golanska E, Sieruta M, Gresner SM, Hulas-Bigoszewska K, Corder EH, Styczynska M, Peplonska B, Barcikowska M, Liberski PP (2008) Analysis of APBB2 gene polymorphisms in sporadic Alzheimer’s disease. Neurosci Lett 447, 164-166.
• Golanska E, Hulas-Bigoszewska K, Sieruta M, Zawlik I, Witusik M, Gresner SM, Sobow T, Styczynska M, Peplonska B, Barcikowska M, Liberski PP, Corder EH (2009) Earlier onset of AD: risk polymorphisms within PRNP, PRND, CYP46 & APOE genes. J Alzheimers Dis, in press.

Cheng-Xin Gong, M.D.

• Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong C-X (2004) O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease. Proc Natl Acad Sci USA 101, 10804-10809.
• Liu F, Iqbal K, Grundke-Iqbal I, Rossie S, Gong C-X (2005) Dephosphorylation of tau by protein phosphatase 5: Impairment in Alzheimer disease. J Biol Chem 280, 1790-1796.
• Liang Z, Liu F, Grundke-Iqbal I, Iqbal K, Gong C-X (2007) Down-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain. J Neurochem 103, 2462-2470.
• Deng Y, Li B, Liu F, Iqbal K, Grundke-Iqbal I, Brandt R, Gong C-X (2008) Regulation between O-GlcNAcylation and phosphorylation of neurofilament-M and their dysregulation in Alzheimer disease. FASEB J 22, 138-145.

Prof. Jürgen Götz

• Götz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta42 fibrils. Science 293, 1491-1495.
• Götz J, Streffer JR, David D, Schild A, Hoerndli F, Pennanen L, Kurosinski P, Chen F (2004) Transgenic animal models of Alzheimer’s disease and related disorders: Histopathology, behavior and therapy. Mol Psychiatr 9, 664-683.
• Chen F, Wollmer A, Hoerndli F, Münch G, Kuhla B, Rogaev EI, Tsolaki M, Papassotiropoulos A, Götz J (2004) Role for glyoxalase I in Alzheimer’s disease. Proc Natl Acad Sci USA 101, 7687-7692.
• David DC, Ittner LM, Gehrig P, Nergenau D, Shepherd C, Halliday G, Götz J (2006) β-Amyloid treatment of two complementary P301L tau-expressing Alzheimer’s disease models reveals similar deregulated cellular processes. Proteomics 6, 6566-6577.

Carlos Alberto Gonçalves, MD, PhD

• Tramontina AC, Tramontina F, Bobermin LD, Zanotto C, Souza DF, Leite MC, Nardin P, Gottfried C, Gonçalves CA (2008) Secretion of S100B, an astrocyte-derived neurotrophic protein, is stimulated by fluoxetine via a mechanism independent of serotonin. Prog Neuropsychopharmacol Biol Psychiatry 32, 1580-1583.
• Swarowsky A, Rodrigues L, Biasibetti R, Leite MC, de Oliveira LF, de Almeida LM, Gottfried C, Quillfeldt JA, Achaval M, Gonçalves CA (2008) Glial alterations in the hippocampus of rats submitted to ibotenic-induced lesion of the nucleus basalis magnocellularis. Behav Brain Res 190, 206-211.
• Vicente E, Degerone D, Bohn L, Scornavaca F, Pimentel A, Leite MC, Swarowsky A, Rodrigues L, Nardin P, Vieira de Almeida LM, Gottfried C, Souza DO, Netto CA, Gonçalves CA (2008) Astroglial and cognitive effects of chronic cerebral hypoperfusion in the rat. Brain Res, in press.
• de Souza DF, Leite MC, Quincozes-Santos A, Nardin P, Tortorelli LS, Rigo MM, Gottfried C, Leal RB, Gonçalves CA (2008) S100B secretion is stimulated by IL-1beta in glial cultures and hippocampal slices of rats: Likely involvement of MAPK pathway. J Neuroimmunol, in press.

Prof. Stefano Govoni

• Lanni C, Uberti D, Racchi M, Govoni S, Memo M (2007) Unfolded p53: a potential biomarker for Alzheimer's disease. J Alzheimers Dis 12, 93-99.
• Lenzken SC, Lanni C, Govoni S, Lucchelli A, Schettini G, Racchi M (2007) Nicotinic component of galantamine in the regulation of amyloid precursor protein processing. Chem Biol Interact 165, 138-145.
• Lanni C, Racchi M, Mazzini G, Ranzenigo A, Polotti R, Sinforiani E, Olivari L, Barcikowska M, Styczynska M, Kuznicki J, Szybinska A, Govoni S, Memo M, Uberti D (2007) Conformationally altered p53: a novel Alzheimer's disease marker? Mol Psychiatry, in press.
• Preda S, Govoni S, Lanni C, Racchi M, Mura E, Grilli M, Marchi M (2007) Acute beta-amyloid administration disrupts the cholinergic control of dopamine release in the nucleus accumbens. Neuropsychopharmacology, in press.

Paula Grammas, Ph.D.

• Hensley K, Ferrell S, Floyd RA, Gordon B, Grammas P, Mhatre M, Mou S, Pye QN, Stewart C, West M, West S, Williamson KS (2004) The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits TNFa activation of microglia and extends survival of G93A-SOD1 transgenic mice. J Neurochem 91, 540-546.
• Christov A, Ottman JT, Grammas P (2004) Vascular inflammatory, oxidative and protease-based proceses: implication neuronal cell death in Alzheimer’s disease. Neurol Res 26, 540-546.
• Kanmogne GD, Primeaux C, Grammas P (2005) HIV-1 gp120 proteins alter tight junction protein expression and brain endothelial cell permeability: Implications for the pathogenesis of HIV-associated dementia. J Neuropathol Exp Neurol 64, 498-505.
• Kanmogne GD, Primeaux C, Grammas P (2005) Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun 333, 1107-1115.

William B. Grant, Ph.D.

• Grant WB (1997) Dietary links to Alzheimer's disease. Alz Dis Rev 2, 42-55.
• Grant WB (2000) Fish consumption, cancer, and Alzheimer disease. Am J Clin Nutr 71, 599-600.
• Grant WB, Campbell A, Itzhaki RF, Savory J (2002) The significance of environmental factors in the etiology of Alzheimer's disease. J Alzheimers Dis 4, 179-189.
• Grant WB (2004) Year 2000 prevalence of Alzheimer disease in the United States. Arch Neurol 61, 802-803.

Dr. Edna Grünblatt

• Grünblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S (2007) Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 101, 757-770.
• Grünblatt E, Zander N, Bartl J, Jie L, Monoranu C.M, Arzberger T, Rivka R, Roggendorf W, Gerlach M, Riederer P (2007) Comparison analysis of gene expression patterns between sporadic Alzheimer's and Parkinson's disease. J Alzheimer Dis 12, 291-311.
• Monoranu CM, Apfelbacher M, Grünblatt E, Puppe B, Alafuzoff I, Ferrer I, Al-Saraj S, Keyvani K, Schmitt A, Falkai P, Schittenhelm J, Halliday G, Kril J, Harper C, Riederer P, Roggendorf W (2008) pH measurement as quality control on human postmortem brain tissue: A Study of the Brain Net Europe Consortium. Neuropath Appl Neurobiol, in press.
• Grünblatt E, Zehetmayer S, Bartl J, Löffler C, Wichart I, Rainer MK, Jungwirth S, Bauer P, Danielczyk W, Tragl KH, Riederer P, Fischer P (2008) Genetic risk factors and markers for Alzheimer's disease and/or depression in the VITA study. J Psych Res, in press.

Elizabeth Head, Ph.D.

• Nistor N, Don M, Parekh M, Sarsoza F, Goodus M, Lopez GE, Kawas C, Leverenz J, Doran E, Lott IT, Hill M, Head E (2007) Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain. Neurobiol Aging 28, 1493-1506.
• Head E, Pop V, Vasilevko V, Hill M, Saing T, Sarsoza F, Nistor M, Christie LA, Milton S, Glabe C, Barrett E, Cribbs D (2008) A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J Neurosci 28, 3555-3566.
• Haier RJ, Head E, Head K, Lott IT (2008) Neuro-imaging of individuals with Down syndrome at-risk for dementia: evidence for possible compensatory events. NeuroImage 39, 1324-1332.
• Head E, Corrada MM, Kahle-Wrobleski K, Kim RC, Sarsoza F, Goodus M, Kawas CH (2008) Synaptic proteins, neuropathology and cognitive status in the oldest-old. Neurobiol Aging, in press.

Sanna-Kaisa Herukka

• Herukka SK, Hallikainen M, Soininen H, Pirttilä T (2005) CSF Abeta and Tau or phosphorylated Tau and prediction of progressive mild cognitive impairment. Neurology 64, 1294-1297.
• Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soininen H, Pirttilä T (2007) CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol Aging 28, 507-514.
• Lämsä R, Helisalmi S, Herukka SK, Tapiola T, Pirttilä T, Vepsäläinen S, Hiltunen M, Soininen H (2008) Genetic study evaluating LDLR polymorphisms and Alzheimer's disease. Neurobiol Aging, in press.
• Ojala J, Alafuzoff I, Herukka SK, van Groen T, Tanila H, Helisalmi S, Pirttilä T (2008) Expression of interleukin 18 is increased in the brain of Alzheimer’s disease patients. Neurobiol Aging, in press.

Lap Ho

• Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18, 902-904.
• Wang J, Ho L, Zhao Z, Seror I, Humala N, Dickstein DL, Thiyagarajan M, Percival SS, Talcott ST, Pasinetti GM (2006) Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J 20, 2313-2320.
• Wang J, Ho L, Zhao W, Ono K, Rosensweig C, Chen L, Humala N, Teplow DB, Pasinetti GM (2008) Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer’s disease. J Neurosci 28, 6388-6392.
• Ho L, Chen LH, Wang J, Zhao W, Talcott ST, Ono K, Teplow D, Humala N, Cheng A, Percival SS, Ferruzzi M, Janle E, Dickstein DL, Pasinetti GM (2009) Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer’s disease-type neuropathology and cognitive deterioration. J Alzheimers Dis 16, in press.

Michael Hoffmann, MD

• Hoffmann M, Schmitt F (2004) Cognitive impairment in isolated subtentorial stroke. Acta Neurol Scand 109, 14-24.
• Hoffmann M, Schmitt F (2006) Metacognition in stroke: Bedside assessment and relation to location, size and stroke severity. Cogn Behav Neurol 19, 85-94.
• Hoffmann M, Schmitt F, Bromley E (2008) Vascular cognitive syndromes: relation to stroke etiology and topography. Acta Neurol Scand, in press.
• Hoffmann M, Schmitt F, Bromley E (2008) Comprehensive cognitive neurological assessment in stroke. Acta Neurol Scand, in press.

Prof. Nigel M. Hooper

• Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ (2003) Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci USA 100, 11735-11740.
• Vardy ERLC, Catto AJ, Hooper NM (2005) Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. Trends Mol Med 11, 464-472.
• Cordy JM, Hooper NM, Turner AJ (2006) The involvement of lipid rafts in Alzheimer's disease. Mol Membr Biol 23, 111-122.
• Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB, Manson JC, Baybutt HN, Turner AJ, Hooper HM (2007) Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci USA 104, 11062-11067.

Koichi Iijima, Ph.D.

• Ando K, Iijima K, Elliott JL, Kirino Y, Suzuki T (2001) Phosphorylation-dependent regulation on the interaction of amyloid precursor protein with Fe65 and the production of beta-amyloid. J Biol Chem 276, 40353-40361.
• Iijima K, Liu H-P, Chiang A-S, Hearn SA, Konsolaki M, Zhong Y (2004) Dissecting the pathological effects of human Aβ40 and Aβ42 in Drosophila: A potential model for Alzheimer disease. Proc Natl Acad Sci 101, 6623-6628.
• Iijima-Ando K, Hearn SA, Granger L, Shenton C, Gatt A, Chiang HC, Hakker I, Zhong Y, Iijima K (2008). Overexpression of neprilysin reduces Alzheimer amyloid β-42 (Aβ42)-induced neuron loss and intraneuronal Aβ42 deposits but causes a reduction in cAMP-responsive element-binding protein-mediated transcription, age-dependent axon pathology, and premature death in Drosophila. J Biol Chem 283, 19066-19076.
• Iijima K, Chiang HC, Hearn SA, Hakker I, Gatt A, Shenton C, Granger L, Leung A, Iijima-Ando K, Zhong Y (2008) Aβ42 mutants with different aggregation profiles induce distinct pathologies in Drosophila. PLoS ONE 3, e1703.

Khalid Iqbal, Ph.D.

• Iqbal K, Flory M, Khatoon S, Soininen H, Pirttila T, Lehtovirta M, Alafuzoff I, Blennow K, Andreasen N, Vanmechelen E, Grundke-Iqbal I (2005) Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol 58, 748-757.
• Wang JZ, Grundke-Iqbal I, Iqbal K (2007) Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 25, 59-68.
• Chen H, Tung YC, Li B, Iqbal K, Grundke-Iqbal I (2007) Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogeneis. Neurobiol Aging 28, 1148-1162.
• Chen S, Li B, Grundke-Iqbal I, Iqbal K (2008) I1PP2A affects tau phosphorylation via association with the catalytic subunit or protein phosphatase 2A. J Biol Chem 283, 10513-10521.

Prof. Ruth Itzhaki

• Wozniak MA, Combrinc M, Wilcock GK, Itzhaki RF (2005) Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer's disease patients. J Med Virol 75, 300-306.
• Itzhaki RF, Wozniak MA (2006) Herpes simplex virus type 1, apolipoprotein E, and cholesterol: a dangerous liaison in Alzheimer’s disease and other disorders. Progr Lipid Res 45, 73-90.
• Wozniak MA, Shipley SJ, Dobson CB, Parker SP, Scott FT, Leedham-Green M, Breuer J, Itzhaki RF,  (2007) Does apolipoprotein E determine outcome of infection by varicella zoster virus and by Epstein Barr virus? Eur J Human Genet 15, 672-678.
• Wozniak MA, Shipley SJ, Itzhaki RF, Dobson CB (2007) Herpes virus-induced amyloid deposition: a major pathway to Alzheimer’s disease. Neurosci Lett. In proof: doi:10.1016/j.neulet.2007.09.077.

Prof. Dr. Rolf Jackisch

• Birthelmer A, Ehret A, Riegert C, Rothmaier AK, Leemhuis J, Jackisch R (2007) Modulation of electrically-evoked serotonin release in cultured rat raphe neurons. J Neurochem 100, 1613-1625.
• Cassel JC, Lazaris A, Birthelmer A, Jackisch R (2007) Spatial reference- (not working- or procedural-) memory performance of aged rats predicts the magnitude of sulpiride- induced facilitation of acetylcholine release by striatal slices. Neurobiol Aging 28, 1270-1285.
• Jackisch R, Gansser S, Cassel JC (2008) Noradrenergic denervation facilitates the release of acetylcholine and serotonin in the hippocampus: Towards a mechanism underlying upregulations described in MCI patients? Exp Neurol 213, 345-353.
• Jackisch R, Foerster S, Kammerer M, Rothmaier AK, Ehret A, Zentner J, Feuerstein TJ (2009) Effects of choline esterase (ChE) inhibitors on ChE activity and acetylcholine release in fresh specimens of rat and human neocortex. J Alzheimers Dis, in press.

Christian P. Jacob, M.D.

• Jacob C, Strobel A, Hohenberger K, Ringel T, Gutknecht L, Reif A, Brocke B, Lesch KP (2004) Association between allelic variation of serotonin transporter function and neuroticism in anxious cluster C personality disorders. Am J Psychiatry 161, 569-572.
• Jacob C, Muller J, Schmidt M, Hohenberger K, Gutknecht L, Reif A, Schmidtke A, Mossner R, Lesch KP (2005) Cluster B personality disorders are associated with allelic variation of monoamine oxidase A activity. Neuropsychopharmacology 30, 1711-1718.
• Gutknecht L*, Jacob C*, Strobel A*, Müller J, Reif A, Mössner R, Zeng Y, Gross C, Brocke B, Lesch KP (2007) Tryptophan hydroxylase-2 gene variation influences personality traits and related disorders. Int J Neuropsychopharmacol 10, 309-320. *contributed as equal.
• Jacob C, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, Ravid R, Roggendorf W, Riederer P, Grünblatt E (2007) Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer’s disease. J Alzheimers Dis 11, 97-116.

  top

Kurt A. Jellinger, M.D.

• Jellinger KA (2006) Clinicopathological analysis of dementia disorders in the elderly--an update. J Alzheimers Dis 9, 61-70.
• Jellinger KA (2007) More frequent Lewy bodies but less frequent Alzheimer-type lesions in multiple system atrophy as compared to age-matched control brains. Acta Neuropathol (Berl) 114, 299-303.
• Jellinger KA, Attems J (2007) Neuropathological evaluation of mixed dementia. J Neurol Sci 257, 80-87.
• Jellinger KA, Attems J (2007) Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease. Acta Neuropathol 113, 107-117.

Zhao-feng Jiang, Ph.D. M.D.

• Dai XL, Sun YX, Jiang ZF (2006) Cu(II) Potentiation of Alzheimer Aβ1-40 cytotoxicity and transition on its secondary structure. Acta Biochim Biophys Sin 38, 765-772.
• Dai XL, Chen CL, Jiang ZF (2007) AβCu(II) complexes associated with Alzheimer’s disease. Proc China Assoc Sci Tech 3, 830-833.
• Dai X-L, Sun Y-X, Jiang Z-F (2007) Attenuated cytotoxicity but enhanced β-fibril of a mutant amyloid β-peptide with a methionine to cystein substitution. FEBS Letters 581, 1269-1274.
• Dai XL, Sun YX, Jiang ZF (2007) Protective effects of vitamin E against oxidative damage induced by Cu(II)Aβ1-40 complexes. Acta Biochim Biophys Sin 39, 123-130.

Vikram Khurana, M.D., Ph.D.

• Khurana V, Lu Y, Steinhilb ML, Oldham S, Shulman JM, Feany MB (2006) TOR-mediated cell- cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr Biol 16, 231-241.
• Fulga TA, Elson-Schwab I,Khurana V, Michelle L Steinhilb, Soires TL, Hyman BT, Feany MB (2007) Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol 9, 139-148.
• Khurana V, Feany MB (2007) Connecting cell-cycle activation to neurodegeneration in Drosophila. Biochim Biophys Acta 1772, 446-456.
• Khurana V (2008) Modeling tauopathy in Drosophila. J Alzheimers Dis, in press.

Wolff M. Kirsch, M.D.

• Coon KD, Siegel AM, Yee SJ, Dunckley TL, Mueller C, Nagra RM, Tourtellottee WW, Reiman EM, Papassotiropoulos A, Petersen FF, Stephan DA, Kirsch WM (2006) Preliminary demonstration of an allelic association of the IREB2 gene with Alzheimer’s disease. J Alzheimers Dis 9, 225-233.
• Magaki S, Mueller C, Dickson C, Kirsch W (2007) Increased production of inflammatory cytokines in mild cognitive impairment. Exp Gerontol 42, 233-240.
• Magaki S, Raghavan R, Mueller C, Oberg KC, Vinters HV, Kirsch WM (2007) Iron, copper, and iron regulatory protein 2 in Alzheimer’s disease and related dementias. Neurosci Lett 4185, 72-76.
• Larsen JP, Britt III W, Kido D, Bartnik Olson BL, Holshouser BA, Kirsch WM (2007) Susceptibility-weighted magnetic resonance imaging in the evaluation of dementia. Radiology Case Reports 2, 1-4.

Daniel Kopf, M.D.

• Kopf D, Frölich L (2007) Therapie der Alzheimer-Krankheit: So setzen Sie Antidementiva richtig ein. [Practical pharmacologic treatment of Alzheimer´s disease] CME-Fortbildung Der Kassenarzt 18, 18-23.
• Weber-Hamann B, Gilles M, Schilling C, Onken V, Frankhauser P, Kopf D, Lederbogen F, Deuschle M (2008) Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine. J Clin Psychopharmacol 28, 581-584.
• Kopf D, Cheng LS, Blandau P, Hsueh W, Raffel LJ, Buchanan TA, Xiang AH, Davis RC, Rotter JI, Lehnert H (2008) Association of insulin sensitivity and glucose tolerance with the c.825C>T variant of the G protein beta-3 subunit gene. J Diabetes Complications 22, 205-209.
• Kopf D, Frölich L (2008) Antidementiva: Stellenwert, Wirksamkeit und Grenzen [Pharmacologic treatment of dementia: significance, efficacy and limitations]. Psychiatr Psychother 2, 285-303.

Jeremy Koppel

• Dreses-Werringloer U, Lambert JC, Vingtdeux V, Zhao H, Vais H, Seibert A, Jain A, Koppel J, Rovelet-Lecrux A, Hannequin D, Pasquier F, Galimberti D, Scarpini E, Mann D, Lendon C, Campion D, Amouyel P, Davies P, Foskett JK, Campagne F, Marambaud P (2008) A polymorphism in CALHM1 influences Ca2+ homeostasis, Aß levles, and Alzheimer's disease risk. Cell 133, 1149-1161.
• Koppel J, Davies P (2008) Targeting the endocannabinoid system in Alzheimer's disease. J Alzheimers Dis 15, 495-504.

Marian L. Kruzel, Ph.D.

• Schuster D, Rajendran A, Hui SW, Nicotera T, Srikrishnan T, Kruzel ML (2005) Protective effect of colostrinin on neuroblastoma cell survival is due to reduced aggregation of beta-amyloid. Neuropeptides 39, 419-426.
• Bacsi A, Stanton J, Hughes T, Kruzel M, Boldogh I (2005) Colostrinin-driven neurite outgrowth requires p53 activation in PC12 cells. Cell Mol Neurobiol 25, 1123-1139.
• Bourhim M, Kruzel M, Srikrishnan T, Nicotera T (2007) Linear quantitation of Aβ aggregation using Thioflavin T: Reduction in fibril formation by colostrinin. J Neurosci Methods 160, 264-268.
• Bacsi A, Woodberry M, Kruzel ML, Boldogh I (2007) Colostrinin delays the onset of proliferative senescence of diploid murine fibroblast cells. Neuropeptides 41, 93-101.

James J. Lah, M.D., Ph.D.

• Agca C, Fritz JJ, Walker LC, Levey AI, Chan AWS, Lah JJ, Agca Y (2008) Development of transgenic rats producing human beta amyloid precursor protein (APP) as a model for Alzheimer's disease. BMC Neurosci 9, 28.
• Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MS, Baldwin RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ (2008) Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 28, 10422-10433.
• Steenland NK, Auman CM, Patel PM, Bartell SM, Goldstein FC, Levey AI, Lah JJ (2008) Development of a rapid screening instrument for mild cognitive impairment and undiagnosed dementia. J Alzheimers Dis 15, 419-427.
• Dodson SE, Karmali V, Fritz JJ, Carter SC, Cheng D, Peng J, Levey AI, Lah JJ (2008) Loss of LR11/SorLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role of LR11 in Alzheimer’s disease. J Neurosci, in press.

Dr. Anis Larbi

• Larbi A, Douziech N, Dupuis G, Khalil A, Pelletier H, Guerard KP, Fülöp T Jr (2004) Age-associated alterations in the recruitment of signal-transduction proteins to lipid rafts in human T lymphocytes. J Leukoc Biol 75, 373-381.
• Fulop T, Larbi A, Wikby A, Mocchegiani E, Hirokawa K, Pawelec G (2005) Dysregulation of T-cell function in the elderly : scientific basis and clinical implications. Drugs Aging 22, 589-603.
• Larbi A, Franceschi C, Mazzatti D, Solana R, Wikby A, Pawelec G (2008) Aging of the immune system as a prognostic factor for human longevity. Physiology (Bethesda) 23, 64-74.
• Koch S, Larbi A, Derhovanessian E, Ozcelik D, Naumova E, Pawelec G (2008) Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun Ageing 5, 6.

Andrew J. Larner

• Du Plessis DG, Larner AJ (2008) Phenotypic similarities causing clinical misdiagnosis of pathologically-confirmed sporadic Creutzfeldt-Jakob disease as dementia with Lewy bodies. Clin Neurol Neurosurg 110, 194-197.
• Larner AJ, Hancock P (2008) Activities of daily living in frontotemporal dementia and Alzheimer disease. Neurology 70, 658.
• Larner AJ (2008) Alzheimer's disease. In Cognitive Neurology. A clinical textbook, Cappa SF, Abutalebi J, Démonet JF, Fletcher PC, Garrard P (Eds). Oxford University Press, Oxford, 199-227.
• Larner AJ (2008) Mutation negative early-onset familial Alzheimer disease: consider screening for tau gene mutations. Alz Dis Assoc Disord 22, 194-195.

Christoph Laske, M.D.

• Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, Soekadar S, Richartz E, Koehler N, Bartels M, Buchkremer G, Schott K (2007) BDNF serum and CSF concentrations in Alzheimer’s disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res 41, 387-394.
• Laske C, Leyhe T, Stransky E, Eschweiler GW, Bueltmann A, Langer H, Stellos K, Gawaz M (2007) Association of platelet-derived soluble glycoprotein VI in plasma with Alzheimer’s disease. J Psychiatr Res, in press
• Leyhe T, Stransky E, Eschweiler GW, Buchkremer G, Laske C (2008) Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 258, 124-128.
• Laske C, Stellos K, Eschweiler GW, Leyhe T, Gawaz M (2008) Decreased CXCL12 (SDF-1) plasma levels in early Alzheimer’s disease: a contribution to a deficient hematopoietic brain support? J Alzheimers Dis, in press.

Prof. Massimo Leandri

• Massimo Leandri, Sharon Cammisuli, Sergio Cammarata, Luigi Baratto, Jackie Campbell, Marina Simonini, Massimo Tabaton (2009) Balance features in Alzheimer’s disease and amnestic mild cognitive impairment. J Alzheimers Dis 16, in press.

Alan Lerner, MD

• Lerner AJ, Strauss MI, Sami SA (2007) Apathy in Alzheimer's disease. Geriatrics 62, 14-17.
• Goodenowe DR, Cook LL , Liu J, Lu Y,  Jayasinghe DA,. Ahiahonu PWK, Heath D, Yamazaki Y, Wood PL, Krenitsky KF, Sparks DL, Lerner A, Friedland R, Kudo T, Kamino K, Morihara, T, Takeda M, Flax J (2007) Serum ethanolamine plasmalogen levels correlate with Alzheimer’s pathology and severity of dementia. J Lipid Res 48, 2485-2498.
• Lerner AJ, Ogrocki PK, Thomas PJ (2008) Network graph analysis of category fluency data. Cogn Behav Neurol, in press.
• McClendon MJ, Hernandez S, Smyth KA, Lerner AJ (2009) Memantine and acetylcholinesterase inhibitor treatment in cases of CDR 0.5 or questionable impairment. J Alzheimers Dis, in press.

Dr. Thomas Leyhe

• Leyhe T, Stransky E, Eschweiler GW, Buchkremer G, Laske C (2008) Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 258, 124-128.
• Laske C, Stransky E, Fritsche A, Eschweiler GW, Leyhe T (2008) Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Aβ 1–42 ratios in CSF in patients with mild Alzheimer’s disease dementia. Eur Arch Psychiatry Clin Neurosci, in press.
• Leyhe T, Milian M, Müller S, Eschweiler GW, Saur R (2008) The minute hand phenomenon in the clock test of patients with early Alzheimer’s disease. J Geriatric Psychiatry Neurol, in press.
• Leyhe T, Eschweiler GW, Stransky E, Gasser T, Annas P, Basun H, Laske C (2009) Increase of BDNF serum concentration in lithium treated patients with early Alzheimer’s disease. J Alzheimers Dis, in press.

Dr. John Lew

• Scaramozzino F, Peterson DW, Farmer P, Gerig JT, Graves DJ, Lew J (2006) TMAO promotes fibrillization and microtubule assembly activity in the c-terminal repeat region of tau. Biochemistry 45, 3684-3691.
• Peterson DW, Zhou HJ, Dahlquist FW, Lew J (2008) A soluble oligomer of tau associated with aggregation analyzed by NMR. Biochemistry 47, 7393-7404.
• Lew J, Zhang L (2009) CDK5: An Historical Account. Trends in Cell Cycle Research. K. Yoshida ed., in press.
• Peterson DW, George R, LaPointe N, Scarramozzino F, Anderson RA, Graves DJ, Lew J (2009) Cinnamon extract inhibits tau aggregation associated with Alzheimer’s disease in vitro. J Alzheimers Dis, in press.

João Pedro Lopes

• Lopes JP, Oliveira CR, Agostinho P (2007) Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-beta and prion peptides. Implications for Alzheimer’s disease and prion-related encephalopathies. Cell Mol Neurobiol 27, 943-957.
• Lopes JP, Oliveira CR, Agostinho P (2008) Cdk5 acts as a mediator of neuronal cell cycle re-entry triggered by amyloid-beta and prion peptides. Cell Cycle, in press.
• Lopes JP, Oliveira CR, Agostinho P (2008) Cell cycle re-entry in AD: a major neuropathological characteristic? Curr Alzheimer Dis, in press.
• Lopes JP, Blurton-Jones M, Yamazaki TR, Agostinho P, LaFerla FM (2009) Activation of cell cycle proteins in transgenic mice in response to neuronal loss but not Aβ and tau pathology. J Alzheimers Dis, in press.

Julio López Bastida

• Lopez-Bastida J, Serrano-Aguilar P, Yanes-Lopez V, Duque-Gonzalez B (2003) Time spent and cost on informal care giving for persons with Alzheimer in Spain. Value Health 6, 764.
• Serrano-Aguilar P, López-Bastida J, Yanes-López V (2006) Impact of caregiving in Alzheimer's disease on quality of life and perceived burden of informal caregivers. Neuroepidemiology 27, 136-142.
• Lopez-Bastida J, Oliva-Moreno J, Serrano-Aguilar P, Perestelo-Pérez L (2006) The social economics costs and quality of life of Alzheimer disease in Spain. Neurology 67, 2186-2191.
• Julio López-Bastida, Warren Hart, Lidia Garcia-Perez, Renata Livertova (2009) Cost-effectiveness of donezepil in the treatment of mild or moderate Alzheimer's disease. J Alzheimers Dis, in press.

Clement Loy

• Loy C, Schneider L (2006) Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev, CD001747.
• Kwok JB, Loy CT, Hamilton G, Lau E, Hallupp M, Williams J, Owen MJ, Broe GA, Tang N, Lam L, Powell JF, Lovestone S, Schofield PR (2008) Glycogen synthase kinase-3beta and tau genes interact in Alzheimer's disease. Ann Neurol 64, 446-454.
• Luty AA, Kwok JB, Thompson EM, Blumbergs P, Brooks WS, Loy CT, Dobson-Stone C, Panegyres PK, Hecker J, Nicholson GA, Halliday GM, Schofield PR (2008) Pedigree with frontotemporal lobar degeneration—motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. BMC Neurol 8, 32.
• Barnes J, Bartlett JW, van de Pol LA, Loy CT, Scahill RI, Frost C, Thompson P, Fox NC (2008) A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging, in press.

Jose Luchsinger

• Luchsinger JA, Tang MX, Shea S, Mayeux R (2004) Hyperinsulinemia and risk of Alzheimer's disease. Neurology 63, 1187-1192.
• Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R (2005) Aggregation of vascular risk factors and risk of incident Alzheimer's disease. Neurology 65, 545-551.
• Luchsinger JA, Reitz C, Patel B, Tang MX, Mayeux R (2007) Relation of diabetes to mild cognitive impairment. Arch Neurol 64, 392-398.
• Luchsinger JA, Patel B, Tang MX, Schupf N, Mayeux R (2007) Measures of adiposity and dementia risk in elderly persons. Arch Neurol 64, 392-398.

Dr. Yuan Luo

• Wu YJ, Luo Y (2005) Transgenic C. elegans as a model in Alzheimer’s research. Curr Alzheimer Res 2, 37-45.
• Wu Y, Wu ZX, Christen Y, Lambert MP, Klein ML, Link CD, Luo Y (2006) Amyloid beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 26, 13102-13113.
• Xu Y, Cui C, Christen Y, Luo Y (2007) Restoration of impaired phosphorylation of cyclic AMP response element binding protein (CREB) by EGb 761 and its constituents in Aβ-expressing neuroblastoma cells. Eur J Neurosci 26, 2931-2939.
• Tchantchou F, Xu Y, Wu Y, Christen Y, Luo Y (2007) EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer’s disease. FASEB J 21, 2400-2408.